Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.

导出原文传递

翻译打印收藏纠错

作者： Scott,Gettinger ^[1] ; Matthew D,Hellmann ^[2] ; Laura Q M,Chow ^[3] ; Hossein,Borghaei ^[4] ; Scott,Antonia ^[5] ; Julie R,Brahmer ^[6] ; Jonathan W,Goldman ^[7] ; David E,Gerber ^[8] ; Rosalyn A,Juergens ^[9] ; Frances A,Shepherd ^[10] ; Scott A,Laurie ^[11] ; Tina C,Young ^[12] ; Xuemei,Li ^[12] ; William J,Geese ^[12] ; Naiyer,Rizvi ^[2]

作者单位： Yale Cancer Center, New Haven, Connecticut. Electronic address: scott.gettinger@yale.edu. ^[1] Memorial Sloan Kettering Cancer Center, New York, New York. ^[2] University of Washington, Seattle, Washington. ^[3] Fox Chase Cancer Center, Philadelphia, Pennsylvania. ^[4] H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. ^[5] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. ^[6] David Geffen School of Medicine at UCLA, Los Angeles, California. ^[7] UT Southwestern Medical Center, Dallas, Texas. ^[8] Juravinski Cancer Centre at McMaster University, Hamilton, Ontario, Canada. ^[9] Princess Margaret Cancer Centre, Toronto, Ontario, Canada. ^[10] Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada. ^[11] Bristol-Myers Squibb, Princeton, New Jersey. ^[12]

关键词 Combination therapy EGFR-mutant NSCLC Erlotinib Nivolumab Programmed death 1 axis inhibitor